Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 380

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 380
---
 makeup of each individual, these diagnostics and treatments may not be as effective. Heritas Diagnostics provides a comprehensive clinical report format that can be used by both physicians and patients to accurately diagnose, proactively manage healthcare, and/or pursue a specific treatment. Heritas Argentina has partnered with CIBIC in Argentina and provides its services to Meyer in Paraguay to provide a comprehensive range of products to a diverse clientele, including patients and health industry professionals, primarily from the private sector. We provide commercial and technical guidance prior to testing. Our process involves partners collecting samples and sending them to our specialized Argentine Wet -Labfor sequencing and data analysis by our bioinformatics team. The results are delivered through digital reports, ensuring efficient delivery with optimized turnaround times. Over the past thirty years, the number of therapeutic modalities with new diagnostic mechanisms has grown significantly. New diagnostic and treatment tools with improved efficacy and safety are being developed and adopted in various markets, some more mature than others. Latin America is still in its early stages, and Argentina is one of the most mature markets in the region. This presents a great opportunity for Heritas Diagnostics to expand its portfolio. Our clinical knowledge and expertise will enable us to capture market share as we expand through additional partnerships, aligning ourselves with the global shift towards personalized medicine, meeting the increasing demand for precision diagnostics, and playing a key role in improving patient care and treatment. Facilities Our current headquarters are located in Rosario, Argentina, where we lease about 146 square meters of office and laboratory space pursuant to leases with a third party and with CIBIC that expire on December 31, 2027 and October 30, 2026, respectively. In our headquarters, new tests and algorithms are developed and commercialized samples from Rewell and Heritas are processed. We also lease an integrated office space, consisting of two apartments, from Compañía de Insumos y Granos SA., in Rosario. The agreement will expire on December 31, 2026. We expect to source suitable additional or alternative spaces that will be available to accommodate our operations as we grow and scale our business. We believe that our facilities are adequate and suitable for our current needs. For more information on our existing facilities and our expansion plans, see “ — Market Opportunity.” 190 Wet-Labs Our Argentine Wet -Labis located in Rosario, Argentina, where samples from both the Rewell platform and Heritas Diagnostics operations are analyzed and processed. In the laboratory we extract the DNA from either the blood, tissue